A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM).
James D. Hilger
No relevant relationships to disclose
James R. Berenson
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Leonard M. Klein
No relevant relationships to disclose
Alberto Bessudo
No relevant relationships to disclose
Peter J. Rosen
No relevant relationships to disclose
Shahrooz Eshaghian
No relevant relationships to disclose
Hilda Chamras
No relevant relationships to disclose
Youram Nassir
No relevant relationships to disclose
Regina A. Swift
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Robert A. Vescio
Honoraria - Celgene